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Human arylamine N-acetyltransferase 1 (NAT1) is a xenobiotic-metabolizing enzyme that
biotransforms aromatic amine chemicals. We show here that biologically-relevant concentrations
of inorganic (Hg2+) and organic (CH3Hg
+) mercury inhibit the biotransformation functions of
NAT1. Both compounds react irreversibly with the active-site cysteine of NAT1 (half-maximal
inhibitory concentration (IC50) = 250 nM and kinact = 1.4  104 M1 s1 for Hg2+ and IC50 = 1.4 lM
and kinact = 2  102 M1 s1 for CH3Hg+). Exposure of lung epithelial cells led to the inhibition of
cellular NAT1 (IC50 = 3 and 20 lM for Hg2+ and CH3Hg+, respectively). Our data suggest that exposure
to mercury may affect the biotransformation of aromatic amines by NAT1.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The acetyl-CoA:arylamine N-acetyltransferase 1 (NAT1) is one
of the two polymorphic human arylamine N-acetyltransferase
(NAT) enzymes which biotransforms various aromatic and hetero-
cyclic amines [1,2]. Aromatic amines (AA) belong to an important
class of occupational and environmental pollutants with genotoxic
and carcinogenic properties [1]. AA are common by-products of
chemical manufacturing, combustion or pyrolysis. Certain AA are
present in cigarette smoke and exposure to these chemicals is
associated to bladder cancer [1]. NAT-dependent activity can lead
either to detoxiﬁcation, mainly through N-acetylation, or to bioac-
tivation due to O-acetylation [1]. NAT1 biotransforms several ther-chemical Societies. Published by E
; NAT1, human arylamine N-
enzyme; IC50, half-maximal
; PAS, p-aminosalicylate
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niversity of Victoria, Victoria,apeutic drugs or environmental AA carcinogens [3]. In addition to
its role in xenobiotic metabolism, NAT1 enzyme has been sug-
gested to be involved in folate metabolism [4,5]. Moreover, recent
data suggest a direct role of NAT1 in breast cancer progression [6–
9]. Contrary to human arylamine N-acetyltransferase 2 which is
mainly expressed in liver and intestinal epithelium, NAT1 is ubiq-
uitously expressed [10–12].
Mercury is a widespread occupational and environmental pollu-
tant mainly emitted from coal combustion or incineration of solid
waste. Mercury is also present in cigarette smoke [13,14]. The ma-
jor target organs for mercury toxicity include respiratory, hepatic
and renal systems [13]. Inorganic (Hg2+) or organic mercury
(CH3Hg+) exerts a wide range of toxic effects through multiple
mechanisms. These chemicals can alter protein functions by inter-
action with important sulfhydryl groups [14,15]. Hg2+ can inhibit
enzymes containing reactive thiols groups in or near their active
site [14,16]. Certain studies suggest that inhibition of xenobiotic-
metabolizing enzymes (XMEs) by mercury may represent an
important mechanism in mercury toxicity [16–18]. In addition,
rabbit liver NAT have been shown to be inhibited by 4-chloromer-
curybenzoic [19]. However, information on the effects of Hg2+ and
CH3Hg+ at biologically-relevant concentrations (tens of micromo-
lars range in tissues) [20] on XME are limited.lsevier B.V. All rights reserved.
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inorganic and organic mercury impair the acetylation of AA by hu-
man NAT1. Hg2+ and CH3Hg+ were also found to inhibit endoge-
nous NAT1 enzyme in lung epithelial cells. The inhibition of
NAT1 by these compounds is a fast irreversible bimolecular pro-
cess that likely relies on the formation of a thiol–Hg bond involving
the cysteine residue present in the NAT1 active site. These data
support that mercury-dependent inhibition of NAT1 may result
in improper biotransformation of aromatic amine pollutants.60
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Fig. 1. Hg2+ and CH3Hg+ inhibit puriﬁed human NAT1 in a dose-dependent manner.
Puriﬁed NAT1 (1 lM) was preincubated with different concentrations of HgCl2 (d)
or CH3HgCl (j) for 10 min at 37 C prior to enzyme assay. The results represent the
means ± S.D. of three experiments.2. Materials and methods
2.1. Materials
Cell culture reagents were from Invitrogen (Cergy, France). All
other reagents were purchased from Sigma–Aldrich (St-Quentin-
Fallavier, France) unless otherwise stated.
2.2. Recombinant enzyme production and puriﬁcation
NAT1 was produced as a 6xHis-tagged protein in Escherichia
coli BL21 (DE3) as previously described [21].
2.3. Enzyme assays
NAT1 activity was measured spectrophotometrically using p-
nitrophenylacetate (PNPA) as the acetyl donor and p-aminosalicy-
late (PAS) as arylamine substrate [22]. Samples containing NAT1
were assayed in a reaction in 25 mM Tris–HCl, pH 7.5 containing
PAS (500 lMﬁnal concentration). Reactions were started by adding
PNPA (2 mM ﬁnal concentration). The reactionmixtures (1 ml, ﬁnal
concentration of NAT1 equal to 30 nM) were incubated for up to
15 min at 37 C, and the reaction was then quenched by adding
SDS (2% ﬁnal concentration). p-Nitrophenol, generated by the
NAT-mediated hydrolysis of PNPA in the presence PAS was quanti-
ﬁed by measuring absorbance at 410 nm. All enzyme reactions
were performed in triplicate, in conditions in which the initial rates
were linear. Controls were carried out in absence of enzyme or PAS.
NAT activity was measured in cell extracts using reverse-phase
HPLC as described previously [23,24]. Extracts (50 ll) were ﬁrst
incubated with aromatic amine substrate (500 lM ﬁnal) in
25 mM Tris–HCl, pH 7.5 at 37 C for 5 min. AcCoA (1 mM ﬁnal)
was added to start the reaction and the reaction mixtures (100 ll
ﬁnal volume) incubated at 37 C (up to 30 min). The reaction was
quenched by addition of 100 ll of ice-cold aqueous perchlorate
(15%, w/v). After centrifugation (5 min at 12 000g), 20 ll of the
supernatant was injected into a C18 reverse-phase HPLC column.
All assays were performed in triplicate under initial reaction rate
conditions. Enzyme activities were normalized according to the
protein concentration of cellular extracts.
2.4. Treatment of NAT1 with mercury compounds and effects of Hg
scavengers and of AcetylCoA
NAT1 (1 lM) was incubated with several concentrations of
HgCl2 or CH3HgCl for 10 min at 37 C and assayed using the PNPA
assay. In certain experiments, incubations with HgCl2 and CH3HgCl
were also carried out in the presence of reduced glutathione (GSH)
at different concentrations. In another set of experiments, NAT1
enzyme was ﬁrst preincubated with HgCl2 or CH3HgCl for 10 min
at 37 C prior to a ﬁnal incubation with GSH for 10 min at 37 C.
All enzymatic assays were carried out in triplicate.
The effects of AcCoA were tested by incubating NAT1 enzyme
(1 lM) with HgCl2 or CH3HgCl in the presence of 2 mM AcCoA or
CoA at different concentrations as described previously [25].2.5. Kinetic analysis
NAT1 was incubated at 37 C with HgCl2 or CH3HgCl under sec-
ond-order conditions (equal concentration of enzyme and of Hg2+
or CH3Hg+) [26] at a ﬁnal concentration of 0.5 lM. Aliquots of
the mixture were taken every 2 min, quenched by dilution with
buffer and the residual enzyme activity assayed. The kinact value
was obtained by ﬁtting the data (residual enzyme activity) to the
following equation: 1/E = 1/E0 + kinact  t, where E, E0 and t represent
free enzyme concentration at time t, the initial enzyme concentra-
tion and time, respectively. Kinetic data were analyzed using Kale-
idaGraph3.5 (Abelbeck/Synergy, USA).
2.6. Effect of HgCl2 and CH3HgCl on cellular NAT1 enzyme
Human A549 bronchoalveolar epithelial cells were grown as
monolayers in DMEM supplemented with 20% (v/v) FBS. Subcon-
ﬂuent cells were washed with PBS and exposed to HgCl2 or
CH3HgCl in 10 ml DMEM for 1 h at 37 C. After incubation, cells
were washed with PBS and scraped into 200 ll of 25 mM Tris–
HCl, pH 7.5, 0.1% Triton X-100 (lysis buffer) containing protease
inhibitors. Extracts were sonicated and centrifuged. Supernatants
were adjusted to the same protein concentration by addition of ly-
sis buffer prior to enzyme assays.
2.7. Statistical analysis
Data are means ± S.D. of three independent experiments per-
formed in triplicate, unless otherwise stated. One-way ANOVA
was performed and followed by Student’s t-test with Bonferroni
correction using Statview 5.0 (SAS Institute Inc., USA).
3. Results and discussion
3.1. Biologically-relevant concentrations of Hg2+ and CH3Hg
+ inhibits
NAT1 activity
Both inorganic (Hg2+) and organic mercury (CH3Hg+) can occur
within the human body after occupational or accidental exposure
to airborne vapours of elemental mercury or to cigarette smoke.
It has been suggested that Hg2+ and CH3Hg+ may impair the activ-
ity of certain XME such as microsomal epoxide hydrolase, UDP-glu-
curonyltransferases and glutathione S-transferases [17,18] with
putative impact on the biotransformation of other xenobiotics.
We analyzed the effects of low levels of Hg2+ and CH3Hg+ on the
3368 N. Ragunathan et al. / FEBS Letters 584 (2010) 3366–3369biotransformation of AA by puriﬁed NAT1 enzyme. As shown in
Fig. 1, exposure of this XME to Hg2+ or CH3Hg+ led to the dose-
dependent inhibition of NAT1 with in vitro half-maximal inhibi-
tory concentration (IC50) values close to 250 nM and 1.4 lM,
respectively. These data suggested that both mercuric compounds
inhibit NAT1 efﬁciently at low biologically-relevant levels [20]. In
addition, Hg2+ appears more potent than CH3Hg+ in agreement
with data reported for other XME inhibited by these compounds
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Fig. 2. Hg2+ and CH3Hg+ inhibit endogenous NAT1 activity in cultured lung
epithelial cells. Subconﬂuent human lung epithelial A549 cells in Petri dishes were
washed and exposed to HgCl2 (d) or CH3HgCl (j) at different concentrations at
37 C for 1 h. NAT1 activity in normalized cell extracts was measured by HPLC using
2-aminoﬂuorene as substrate. Error bars indicate the S.D. values.
Table 1
AcCoA protects NAT1 from Hg2+ and CH3Hg+-dependent inhibition.
Conditions NAT1 activity (% of control)
NAT1 + HgCl2 (1 lM) 5 ± 1
NAT1 + HgCl2 + CoA (2 mM) 9 ± 2
NAT1 + HgCl2 + AcCoA (2 mM) 50 ± 2*
NAT1 + CH3HgCl (5 lM) 12 ± 3
NAT1 + CH3HgCl + CoA (2 mM) 14 ± 4
NAT1 + CH3HgCl + AcCoA (2 mM) 57 ± 5*
* P < 0.05 versus Hg2+ or CH3Hg+-inhibited NAT1.
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Fig. 3. Effect on GSH on Hg2+ or CH3Hg+-dependent inhibition of NAT1. (A) NAT1 (1 lM
10 min at 37 C and further incubated with 5 mM or 10 mM concentrations of GSH (10 m
three experiments. *P < 0.05 versus NAT1 activity in control. (B) NAT1 was incubated with
the enzyme assay. Grey and black bars represent HgCl2 or CH3HgCl-treated samples, respe
NAT1 activity in control. #P < 0.05 versus Hg2+ or CH3Hg+-inhibited NAT1.One of the main routes of exposure to mercuric compounds is
by inhalation and these chemicals display pulmonary toxicity
[13]. Lung epithelial cells are known to be exposed to mercuric
compounds [27] and to AA present in cigarette smoke [24]. In addi-
tion, lung epithelial cells express several XME that are involved in
the biotransformation of inhalated xenobiotics [28] including
NAT1 [24]. Exposure of human lung epithelial cells (bronchoalveo-
lar A549 cell line) to Hg2+ and CH3Hg+ led to a similar dose-depen-
dent inhibition of the endogenous NAT1 enzyme with IC50 close to
3 lM (for Hg2+) and 20 lM (for CH3Hg+) (Fig. 2). As observed with
the puriﬁed NAT1 enzyme, we found that inorganic mercury was a
more potent inhibitor than the organic form towards cellular
NAT1. Interestingly, a similar effect was observed with cytochrome
P450-dependent hydroxylation of benzo[a]pyrene in lung extracts
which was found to be more affected by Hg2+ than by CH3Hg+ (IC50
of 8 and 20 lM, respectively) [18]. IC50 values around 20 lM were
reported for the inhibition of soluble and microsomal epoxide
hydrolase from human, rat and mouse by Hg2+ [17]. Moreover,
UDP-glucuronyltransferase and glutathione S-transferase activities
in lung extracts were found to be inhibited by Hg2+ with IC50 close
to 80 lM [18]. Our data suggest that the NAT1-dependent activity
is highly sensitive to both Hg2+ and CH3Hg+ and is inhibited by low
biologically-relevant levels of these compounds. Taken together
our results strongly support that several XME biotransformation
pathways may be impaired by mercury.
3.2. Molecular and kinetic mechanisms of inhibition of NAT1 activity
by Hg2+ and CH3Hg
+
Although the mechanism of Hg2+ and CH3Hg+ toxicity remains
unclear, these compounds are known to alter protein function by
interacting irreversibly with certain cysteinyl sulfhydryls to form
stable adducts [14]. NAT enzyme activities depend on a reactive ac-
tive-site cysteine residue which during the catalytic reaction can
be speciﬁcally acetylated by AcCoA to form a transient covalent
acetyl-enzyme. Table 1 indicates that preincubation of NAT1 en-
zyme with AcCoA provided a signiﬁcant protection against Hg2+
and CH3Hg+-dependent inhibition (50–57% protection for 2 mM
AcCoA). On the contrary, CoA the product of AcCoA hydrolysis that
cannot acetylate the cysteine residue present in enzyme’s active
site did not provide any protection. These data clearly suggest that
inhibition of the NAT1 enzyme is due to the reaction of the mercu-
ric compounds with the active-site cysteine residue. Further kinet-
ics analysis under second-order conditions indicate that the40
60
80
100
%
 A
ct
iv
ity
*
#
0
20
HgCl2 (1 µM)
CH3HgCl (5 µM)
Control GSH
(1 mM)
GSH
(5 mM)
) was preincubated with 1 lM HgCl2 (white bars) or 5 lM CH3HgCl (grey bars) for
in at 37 C) prior to activity measurement The results represent the means ± S.D. of
the mercuric compounds (see above) in the presence of 1 mM or 5 mM GSH prior to
ctively. The results represent the means ± S.D. of three experiments. *P < 0.05 versus
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irreversible fast bimolecular process with a second-order rate con-
stant for inhibition equal to 1.4  104 M1 s1 for Hg2+. This pro-
cess occurs rapidly when compared to other enzymes such as
liver glutathione peroxidase which has been shown to be irrevers-
ibly inhibited by Hg2+ with a second-order rate constant for inhibi-
tion equal to 2  102 M1 s1 [29]. Reaction of NAT1 with CH3Hg+
was slower when compared to Hg2+ since the second-order rate
constant for inhibition of NAT1 was found to be equal to
2.2  102 M1 s1.
Reduced glutathione (GSH) is known to be a key cellular scaven-
ger of mercuric compounds through the formation of stable GSH–
metal conjugates. It has been reported that GSH is the primary
non-protein thiol bound to mercury [14]. Physiological concentra-
tions of GSH are close to 1–2 mM, although concentrations up to
10 mM have been reported in certain circumstances [30]. In addi-
tion, exposure to inorganic and organic forms of mercury are
known to deplete the intracellular pool of GSH [14]. As shown in
Fig. 3A, GSH at high concentration (5 mM) did not signiﬁcantly re-
verse Hg2+ and CH3Hg+-dependent inhibition. A weak reactivation
(30% of control activity) was obtained with the highest concen-
tration of GSH (10 mM). This data support the irreversible nature
of the reaction of these mercuric compounds with the enzyme
through the formation of a Hg–thiol bond [14]. Co-incubation of
NAT1 with a low concentration of Hg2+ or CH3Hg+ (1 lM or
5 lM, respectively) in the presence of 1 mM GSH protected par-
tially (30% residual activity for Hg2+ and CH3Hg+) (Fig. 3B). At
5 mM GSH, protection was close to 70% for Hg2+ and CH3Hg+
(Fig. 3B). These results may explain, at least in part, why the intra-
cellular environment of lung cells (GSH concentration around 1–
2 mM) did not fully protect the endogenous NAT enzyme from
inhibition by biologically-relevant levels of Hg2+ or CH3Hg+
(Fig. 3B).
It has been suggested that the inhibitory effects of mercuric
compounds such as Hg2+ and CH3Hg+ on certain XME (such as
UDP-glucuronyltransferases) is of importance, as the alteration of
their activity may lead to generation and/or accumulation of haz-
ardous xenobiotics [16,18]. Our data adds to this and suggest that
in addition to UDP-glucuronyltransferases and glutathione S-trans-
ferases, NAT1 is a phase II-XME sensitive to low levels of mercuric
pollutants.
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